Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04970290
Other study ID # ReGl/20/DTh-Rej/002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 6, 2021
Est. completion date June 15, 2023

Study information

Verified date April 2022
Source Relife S.r.l.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The scope of this clinical trial is to evaluate and confirm thereshaping effect of the face with Definisse Threads double needle and Definisse threads free floating insertion, at day 30. 6 clinical follow up visit will be performed


Description:

The scope of this clinical trial is to evaluate and confirm thereshaping effect of the face with Definisse Threads double needle and Definisse threads free floating insertion, at day 30. 6 clinical follow up visit will be performed to evaluate the modification of skin surface characteristics, the reshaping effect of the face, the subject's satisfaction at each visit, the presence/absence of the threads after the implantation and the global pain perception during the implant procedure..


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date June 15, 2023
Est. primary completion date February 21, 2023
Accepts healthy volunteers No
Gender Female
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: 1. Women, aged between 30 and 60 years (inclusive), looking for aesthetic procedures to improve the aspect of their midface and lower face. 2. Caucasian race. 3. Subjects, as per Investigator's assessment, with the degree of laxity in the middle and lower face belonging to 1-7 classes (inclusive), according to the Facial Laxity Rating Scale. 4. Subjects calm and controlled, according to the Investigator's opinion. 5. Subjects with cooperative attitude, able to comprehend the full nature and the purpose of the investigation, including possible risks, side effects and discomforts and willing to adhere to the study schedule (including attendance to the planned visits) and study prescriptions. 6. Written informed consent release prior to any study-related procedures Exclusion Criteria: Absolute exclusion criteria Subjects presenting one or more of the following absolute exclusion criteria will not be eligible to enter the study. 1. Pregnant and breast-feeding women. 2. Subjects affected by body dysmorphic disorders. 3. Subjects with known allergy/hypersensitivity to threads components and/or lidocaine and/or clarithromycin. 4. Subjects with chronic urticaria. 5. Subjects with Quincke's edema. 6. Subjects with facial plastic surgery within previous 2 years. 7. Subjects with haemostatic or coagulation disorders (haemophilia, haemoglobin pathology, thalassemia major). 8. Subjects with active localized infection (ear, nose, or throat infections, dental abscess, periodontitis), active generalized infection (gastroenteritis, urinary bladder infection) or systemic infection (example: tuberculosis). 9. Subjects with generalized skin conditions or connective tissue disease (prominent scars, keloid, bullous diseases, cutaneous collagenosis, active psoriasis, connective tissue diseases). 10. Subjects with parotid hypertrophy. 11. Immunocompromised, oncological, diabetic subjects or with active Hashimoto's disease. 12. Subjects who underwent dental procedures within previous 2 weeks. 13. Subjects with conditions potentially causing a Koebner response. 14. Subjects with surgical medical treatments previously performed in the implant area or in the surrounding areas within previous 2 months. 15. Subjects with permanent or semi-permanent implants in the area that will be treated. 16. Subjects with active skin infection (impetigo, herpes simplex, massive demodex folliculorum, Pityrosporum, Propionibacterium acnes, viral warts). 17. Obesity. 18. Subjects who are hard smokers (more than 19 cigarettes/day). 19. Any other clinical condition that upon the judgement of the Investigator contraindicates the treatment with threads. Relative exclusion criteria Subjects presenting with one or more of the following relative exclusion criteria will be eligible to enter the study on the basis of the Investigator's evaluation. 1. Subjects with severe ptosis. 2. Anxious subjects. 3. Subjects with melasma and post-inflammatory hyperpigmentation. 4. Subjects with non-infectious gastrointestinal conditions like Crohn's disease or ulcerative colitis. 5. Subjects with hypertension, using anti-inflammatory and/or anticoagulant/antiaggregant medications. 6. Subjects who received filler injections or neurotoxin injection within the previous 2 months. 7. Subjects with inflammatory conditions of the skin. 8. Subjects who are mild-moderate smokers. 9. Subjects having menstruation during the day of the treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Definisse threads free floating and definisse threads double needle
Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30

Locations

Country Name City State
Italy MULTIMED poliambulatorio and day surgery Bologna Italia

Sponsors (1)

Lead Sponsor Collaborator
Relife S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Volume of midface and lower face with Definisse threads double needle and Definisse threads free floating insertion at day 30 The primary objective of this clinical investigation is to evaluate the reshaping effect of the face with Definisse™ thread double needle and Definisse™ thread free floating insertion, at Day 30, through 3D photos and 2D photos, through VECTRA®H2 up to 30 days of treatment
Secondary reshaping effect between baseline and T15d, T4m, T8m, T12m. To evaluate the reshaping effect of the face with Definisse™ threads between baseline and day 15, 4 months, 8 months, 12 months with GAIS (Global Aesthetic Improvement Scale; 5-item scale, where 1 = exceptional improvement, 2 = very improved, 3 = improved, 4 = unaltered, 5 = worsened.)) up to 15 days, 4 months, 8 months and 12 monts of tratment
Secondary To evaluate the modification of skin surface characteristics at 30 days, 4 months, 8 months and 12 monts from baseline Modification of skin surface characteristics in terms of wrinkles, pores and texture, that will be evaluated and quantified at day 30d, 4 months, 8 months, 12 months from baseline through ANTERA 3D. up to 30 days, 4 months, 8 months and 12 monts of tratment
Secondary to evaluate the subject's satisfaction at each visit (1 day, 15 days, 30 days, 4 months, 8 months and 12 monts) Subject's satisfaction self-assessment on the reshaping effect according to the Global Aesthetic Improvement Scale (GAIS: 5-item scale, where 1 = exceptional improvement, 2 = very improved, 3 = improved, 4 = unaltered, 5 = worsened.) at each visit (1 day, 15 days, 30 days, 4 months, 8 months and 12 monts). up to 1 day, 15 days, 30 days, 4 months, 8 monts and 12 months of treatment
Secondary To assess the clinical evaluation of reshaping effect of the total, middle and lower face comparing baseline to T15d, T30d, T4m, T8m, T12m by the non-treating investigators Aesthetic changes of the total, middle and lower face according to the Global Aesthetic Improvement Scale (GAIS: 5-item scale, where 1 = exceptional improvement, 2 = very improved, 3 = improved, 4 = unaltered, 5 = worsened) by the non-treating investigators (one plastic surgeon and one dermatologist) as clinical evaluation of reshaping effect, comparing baseline to T15d, T30d, T4m, T8m, T12m, by evaluating the 2D photos collected by VECTRA®H2 up to 15 days, 30 days, 4 months,8 months, 12 months of treatment
Secondary To evaluate the presence/absence of the threads after the implantation at T30d, T4m, T8m, T12m Presence/absence of the thread in the implant area after 30 days, 4 months, 8 months and 12 monts from the treatment with an ultrasound evaluation. up to 30 days, 4 months, 8 months, 12 months of treatment
Secondary To evaluate the global pain perception during the implant procedure at T1d and T15d. Global pain perception during the implant procedure at 1 day and at the first follow-up visit (15 days) by a numeric pain scale (NRS: from "0" (No pain) to "10" (worst possible pain)). up to 1 and 15 days of treatment
Secondary To evaluate the subject's self-esteem at each visit (1 day, 15 days, 30 days, 4 months, 8 months and 12 monts) T30d, T4m, T8m, T12m). Subject's self-esteem by the Rosenberg Self-Esteem Scale at each visit ( This scale is a widely used self-report instrument for evaluating individual self-esteem. The scale ranges from 0 to 30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.)(1 day, 15 days, 30 days, 4 months, 8 months and 12 monts) up to 1 day, 15 ddays, 30 days, 4 months, 8 month, 12 months of treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05177380 - Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis N/A
Active, not recruiting NCT05400551 - Craneofacial Injuries in Rink Hockey Athletes
Completed NCT05840445 - Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles Phase 4
Recruiting NCT03926403 - Evaluation of the Effectiveness of Hypnosis Support on Patient Perception of Outpatient Surgery Under Local Anaesthesia N/A
Completed NCT04980586 - Cheeks Appearance as a Novel Predictor of Obstructive Sleep Apnea The CASA Score Study
Not yet recruiting NCT04745247 - Stimulate the Face to Improve Tactile Acuity on the Hand N/A
Completed NCT03369028 - Fitting of Commonly Available Face Masks for Late Preterm and Term Infants